Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity …
About Cingulate®
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity …
Pipeline - Cingulate Inc
Cingulate currently has three (3) product candidates, CTx-1301 (dexmethylphenidate), CTx-1302 (dextroamphetamine) and CTx-2103 (anxiety) in the pipeline. All three therapies utilize …
Press Releases - Cingulate Inc
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE …
Dr. Alice Mao, MD - Advisors | Cingulate Inc
The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in …
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric …
May 20, 2025 · Last month Cingulate announced positive top-line results of a high dose (50-mg) food effect study for CTx-1301, with the primary endpoints establishing that it can be taken …
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent …
Jul 29, 2025 · With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop …
0001493152-24-004061 | 8-K | iXBRL Viewer | Cingulate INC
Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).
Events & Presentations - Cingulate Inc
Jun 16, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx …